Opdivo shows promising results in Phase I/II trial
An early-stage trial has shown promising results for Bristol-Myers Squibb’s Opdivo in combination with Nektar Therapeutics’ bempegaldesleukin as first-line treatment for urothelial carcinoma.
Read More
